Clinical Trials Sponsored by Seragon Pharmaceuticals

Total 19846 results

Seagen Inc.
Bristol-Myers Squibb

Active, not recruiting

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Australia, Czechia, Italy, Spain, Poland
Seagen Inc.
Bristol-Myers Squibb

Completed

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Hodgkin Disease | Peripheral T Cell Lymphoma

United States, Canada
Providence Health & Services
Seagen Inc.

Withdrawn

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. (2019-101826)

Breast Cancer Stage IV

United States
Massachusetts General Hospital
Seagen Inc.

Completed

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Cancer

Japan
Cascadian Therapeutics Inc.

Completed

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

Healthy

United States
Massachusetts General Hospital
Seagen Inc.

Terminated

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)

GVHD | Graft-vs-Host Disease

United States
Cascadian Therapeutics Inc.

Completed

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

Healthy Volunteer

United States
Cascadian Therapeutics Inc.

Completed

Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors

Solid Tumors

United States
Cascadian Therapeutics Inc.

Completed

Study of PX-866 and Docetaxel in Solid Tumors

Non Small Cell Lung Cancer (NSCLC) | Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Canada
Aragon Institute of Health Sciences

Completed

Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action

Healthy Volunteers

Spain
Astellas Pharma Inc
Seagen Inc.

Completed

A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer

Prostate Neoplasms

United States
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

Healthy Volunteers

United States
Portola Pharmaceuticals

Withdrawn

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

AITL | Peripheral T-Cell Lymphoma (PTCL NOS) | Nodal Lymphomas of T Follicular Helper (TFH) | Follicular T-cell Lymphoma (FTCL) | ALCL | HSTCL | EATL I,II | MEITL, EATL Type II | Nasal Lymphoma
Portola Pharmaceuticals

Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

United States
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Healthy

Belgium
Ferring Pharmaceuticals
Xanodyne Pharmaceuticals

Completed

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

Menorrhagia

United States
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Squamous Cell Carcinoma of the Oropharynx | HPV16 Positive

Netherlands, United States, United Kingdom, France, Belgium, Czechia, Spain, Italy, Germany, Brazil, Hungary, Mexico, Poland
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Portola Pharmaceuticals

Withdrawn

BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

Venous Thromboses

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Completed

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Seizures | Tuberous Sclerosis Complex

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Pharmacokinetic Evaluation of Testosterone Gel (1%)

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx

United States, Israel, Belgium, Germany, Spain, United Kingdom, Italy, France, Czechia
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Terminated

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Rett Syndrome | RTT

United States, Canada, Italy, Spain, United Kingdom, Australia
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
NovaBay Pharmaceuticals, Inc.
Novum Pharmaceutical Research Services; International Dermatology Research,...

Completed

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

Impetigo

Dominican Republic
PETHEMA Foundation
Millennium Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research...

Completed

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

Multiple Myeloma

Spain
Seagen Inc.
RemeGen Co., Ltd.

Recruiting

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Stomach Neoplasms | Breast Neoplasms | Triple Negative Breast Neoplasms | Gastroesophageal Junction Adenocarcinoma | HER2 Positive Breast Neoplasms | HER2 Low Breast Neoplasms

United States
Criterium, Inc.
Novartis; Seagen Inc.

Recruiting

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

HER2-positive Metastatic Breast Cancer

United States
Bristol-Myers Squibb
Seagen Inc.

Completed

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)

Non-Hodgkin's Disease

United States, France, Canada, United Kingdom, Italy, Spain
Cogent Biosciences, Inc.
Seagen Inc.

Terminated

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Cascadian Therapeutics Inc.

Completed

Phase 1 Study of ONT-10 in Patients With Solid Tumors

Solid Tumors

United States
Cascadian Therapeutics Inc.

Completed

Phase I Trial of Oral PX-866

Advanced Solid Tumors

United States
Aragon Institute of Health Sciences

Unknown

Randomised Controlled Trial of Memantine in Fibromyalgia

Fibromyalgia

Spain
Douglas Pharmaceuticals America Ltd
Novum Pharmaceutical Research Services; ACM Global Laboratories

Completed

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

Tinea Pedis

Belize, United States
Diamyd Inc
Paragon Biomedical; invivodata, Inc.

Completed

NP2 Enkephalin For Treatment of Intractable Cancer Pain

Neoplasms | Intractable Pain

United States
Bristol-Myers Squibb
Seagen Inc.

Active, not recruiting

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)

Hodgkin Disease

United Kingdom, United States, Poland, Spain, Canada, Czechia, France, Germany, Ireland, Italy, Netherlands
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Korea, Republic of, Spain, France, Germany, Italy, Japan, Netherlands
Seagen Inc.
Bristol-Myers Squibb

Completed

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Aragon Institute of Health Sciences

Completed

Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study

Barrett's Esophagus

Spain
Virginia Commonwealth University
Seagen Inc.

Completed

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Mycosis Fungoides | Sézary Syndrome

United States
Aragon Institute of Health Sciences

Completed

Epigenetics Modifications in Morbid Obesity and Obstructive Sleep Apnea Patients: The EPIMOOSA Study (EPIMOOSA)

Obstructive Sleep Apnea | Morbid Obesity | Epigenetic Disorder
Cascadian Therapeutics Inc.

Completed

Phase I Trial of PX-478

Lymphoma | Advanced Solid Tumors

United States
Cascadian Therapeutics Inc.

Completed

A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer

Metastatic Cancer | Advanced Cancer

United States
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Cascadian Therapeutics Inc.

Terminated

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Advanced BRAF-mutant Cancers

United States

Clinical Trials Sponsored by Seragon Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations